Aurobindo Pharma receives warning letter from US FDA for API facility

Aurobindo Pharma receives warning letter from US FDA for API facility

AgenciesUpdated: Friday, January 14, 2022, 04:40 PM IST
article-image
The company that it will be engaging with the regulator and is fully committed to resolving the issue at the earliest. |

Aurobindo Pharma has received a warning letter from the US health regulator for its Hyderabad-based unit I, an API (active pharmaceutical ingredient) manufacturing facility.

This move follows the recent inspection of the facility by the US Food and Drug Administration (US FDA) in August 2021, the company said.

The company added that it will be engaging with the regulator and is fully committed to resolving the issue at the earliest.

The company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe, it stated.

The company believes that this will not impact the existing business from this facility.

(With inputs from PTI)

RECENT STORIES

Game-Changing Alliance: Ambani's Reliance Ventures Into Adani's Power For The First Time; Acquires...

Game-Changing Alliance: Ambani's Reliance Ventures Into Adani's Power For The First Time; Acquires...

SRM Contractors IPO Subscribed 86.57 Times On Last Day Of Bidding

SRM Contractors IPO Subscribed 86.57 Times On Last Day Of Bidding

Tax-Saving Tip From Zerodha CEO Nithin Kamath: 'If You're Married And Hindu..."; Here's How To Save...

Tax-Saving Tip From Zerodha CEO Nithin Kamath: 'If You're Married And Hindu...

Holy Cities Like Ayodhya, Varanasi Attracting Big Retail Brands: Report

Holy Cities Like Ayodhya, Varanasi Attracting Big Retail Brands: Report

A Big Relief For Byju's: NCLT Rejects Investor Plea To Stay Byju's Rights Issue EGM On March 29 Amid...

A Big Relief For Byju's: NCLT Rejects Investor Plea To Stay Byju's Rights Issue EGM On March 29 Amid...